Neutrolis

Cambridge, MA · Founded 2017 · Privately Held (backing)

Operator of a biotechnology company intended to develop therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis is based in Cambridge, MA and was founded in 2017. It was valued at $76.6 million at its later-stage round in Jul 2025, the last priced event on record. It has raised $48 million across 3 recorded rounds; the latest was a $3.5 million seed round in Jun 2025.

PMV mark · valuation
$76.6M
Oct 2026
Priced at
its later-stage round
Jul 2025
Total raised
$48.0M
Last round
Seed Round
Jun 2025

Who backs Neutrolis?

7 investors
InvestorType
Morningside GroupVenture capital
Oceanpine CapitalGrowth equity
First Rice Capital—
LabCentral—
PBJ Capital—
Prefix Capital—
U.S. Department of Health and Human Services—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Neutrolis investors

7 investors are on record for Neutrolis, including Morningside Group, Oceanpine Capital, First Rice Capital and LabCentral. The seed round in Jun 2025 drew 1 investor.

Free account
More of Neutrolis with a free account
  • ·Watch Neutrolis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 7 firms already write checks for companies like Neutrolis. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View